Dr. Lucien is a lawyer and patent agent with over 20 years of experience as legal counsel and patent counsel for innovative Pharma and Biotech public companies. As patent counsel, he prosecuted the patent portfolio for Aurinia Pharmaceutical’s flagship registered product Lupkynis (voclosporin). The focus of his practice has been strategic
Dr. Lucien is a lawyer and patent agent with over 20 years of experience as legal counsel and patent counsel for innovative Pharma and Biotech public companies. As patent counsel, he prosecuted the patent portfolio for Aurinia Pharmaceutical’s flagship registered product Lupkynis (voclosporin). The focus of his practice has been strategic intellectual property portfolio development, product development, and preparing companies for financing and licensing transactions. In addition to his legal credentials, Jamie holds an M.Sc. in Experimental Pathology, and a Ph.D. in Medical Sciences (Immunology).
John has over 35 years of experience in the Life Sciences sector covering Pharma/Biotech, Lab Diagnostics and Medical Devices. He possesses a successful track record of innovative technology commercialization including market assessment, reimbursement, KOL development, product launch and distribution strategies on a global basis. John als
John has over 35 years of experience in the Life Sciences sector covering Pharma/Biotech, Lab Diagnostics and Medical Devices. He possesses a successful track record of innovative technology commercialization including market assessment, reimbursement, KOL development, product launch and distribution strategies on a global basis. John also has successfully managed full P/L responsibility in lab diagnostics and has executed licensing agreements in the pharma/biotech space.
Prior to co-founding Vesmyr Life Sciences, John was Senior Director of Business Development at Isotechnika Pharma (Aurinia) where his responsibilities included all related BD activities globally in support of licensing lead compounds in development for transplant and autoimmune indications which included identifying and securing strategic license partnerships negotiations, due diligence, market analysis, term sheets and valuations.
Dr. Trepanier has over 25 years’ field experience in the pharmaceutical industry with strong emphasis on developing drugs from early discovery stages up to and beyond First-in-Human clinical studies. He has direct hands-on expertise in drug discovery, analytical and bioanalytical method development and analysis, preclinical pharmacokineti
Dr. Trepanier has over 25 years’ field experience in the pharmaceutical industry with strong emphasis on developing drugs from early discovery stages up to and beyond First-in-Human clinical studies. He has direct hands-on expertise in drug discovery, analytical and bioanalytical method development and analysis, preclinical pharmacokinetic, toxicological and toxicokinetic studies, formulation development, drug manufacturing, preparation of regulatory submissions for First-in-Human studies, and interfacing with contract research organizations and patent attorneys. Dr. Trepanier is the developer of Aurinia Pharmaceuticals’ voclosporin commercial formulation as well as Hepion Pharmaceuticals’ rencofilstat formulation.
Dr. Trepanier holds a BSc degree in chemistry and an MSc degree in biochemistry (Concordia University, Quebec), and a PhD in clinical chemistry (University of Windsor, Ontario). He completed a postdoctoral fellowship (University of Alberta) specializing in bioanalytical chemistry. Dr. Trepanier is the author or co-author of numerous scientific papers, abstracts and patents.
Dr. Ure earned his Ph.D. in neurobiology at the University of Alberta (Canada) in 1997, followed by a postdoctoral research fellowship at Mayo Clinic (Rochester, Minnesota) studying mouse models of multiple sclerosis. Over six years at Mayo Clinic Dr. Ure expanded his knowledge and methodologic expertise in virology, neurology, and immuno
Dr. Ure earned his Ph.D. in neurobiology at the University of Alberta (Canada) in 1997, followed by a postdoctoral research fellowship at Mayo Clinic (Rochester, Minnesota) studying mouse models of multiple sclerosis. Over six years at Mayo Clinic Dr. Ure expanded his knowledge and methodologic expertise in virology, neurology, and immunology.
In 2003 Dr. Ure joined Isotechnika Pharmaceuticals (Edmonton, Canada) as a Research Scientist to investigate mechanisms of action and toxicologic properties of the immunosuppressive compound, voclosporin, related to solid organ transplantation. Voclosporin (brand name Lupkynis) was eventually advanced by Aurinia Pharmaceuticals and received FDA approval for treatment of lupus nephritis in January, 2021. Also participating in Isotechnika’s drug discovery program, Dr. Ure developed and performed most of the screening assays and in partnership with Dr. Daniel Trepanier identified the small molecule, rencofilstat, for clinical development. Joining ContraVir Pharmaceuticals in 2016, Dr. Ure helped to obtain IND status and advance rencofilstat in clinical trials for chronic hepatitis B. ContraVir was renamed Hepion Pharmaceuticals in 2018, and rencofilstat development pivoted to fatty liver disease (NASH/MASH). As Chief Scientific Officer at Hepion, Dr. Ure managed nonclinical research and participated in a range of business activities to advance rencofilstat.
Dr. Ure has acquired research experience over the past 34 years across diverse scientific and health disciplines and over the past 20 years in small biotech has participated in most aspects of bench-to-bedside development including drug discovery, intellectual property, CMC, regulatory, clinical, and business development. These experiences and the many biotech successes and failures witnessed over this time have honed Dr. Ure’s focus in advancing new medicinal agents to market.
Dr. Abel has over 35 years of experience in the pharmaceutical industry, having held positions of increasing responsibility progressing from Research Chemist to Senior Director, Chemistry and Manufacturing. He has direct hands-on expertise in drug discovery, lead optimization, chemical process development and scale-up, drug substance and
Dr. Abel has over 35 years of experience in the pharmaceutical industry, having held positions of increasing responsibility progressing from Research Chemist to Senior Director, Chemistry and Manufacturing. He has direct hands-on expertise in drug discovery, lead optimization, chemical process development and scale-up, drug substance and drug product manufacturing, stability studies, due diligence, preparation of regulatory submissions, and oversight of third-party contract research and contract manufacturing organizations. Dr. Abel has the unique experience of having worked directly on the development of a current commercial product every step of the way from its conception through to regulatory approval and successful commercialization.
Dr. Abel holds a BSc degree in chemistry from the University of Alberta and a PhD in pharmaceutical chemistry from Tohoku Pharmaceutical University, Sendai, Japan. He is the author or co-author of numerous scientific papers, abstracts and patents.
AJ has over 30 years of experience in Microcomputers, Cloud Administration, & Application support in the Life Sciences sector. AJ worked for such companies as Aurinia Pharmaceuticals, Hepion Pharmaceuticals & other smaller North American Biotech companies. He worked for Compugen as Senior Microcomputer Systems Engineer supporting the G
AJ has over 30 years of experience in Microcomputers, Cloud Administration, & Application support in the Life Sciences sector. AJ worked for such companies as Aurinia Pharmaceuticals, Hepion Pharmaceuticals & other smaller North American Biotech companies. He worked for Compugen as Senior Microcomputer Systems Engineer supporting the Government of Alberta & local Edmonton businesses. He joined Isotechnika Pharma in 2001 as Senior Director, Information Technology where he was responsible for managing staff to take care of the facility and administration side of operations in Edmonton and remote locations in both Canada and the USA, building and administering the computer, telephone and security networks (locally and remotely), security access and video surveillance, communications (phones, video conferencing, etc.) addressing the technical and business needs of the company.
Copyright © 2024 Vesmyr Life Sciences - All Rights Reserved.
Powered by GoDaddy